Pharmaceuticals
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
ROCKVILLE, Md. and SUZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-01-11 00:00
4129
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
TOKYO, Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' ant...
2023-01-10 21:05
3186
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
* Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market * FDA market authorization advances personalized cancer care in Asia * Clearance sets the stage for continued R&D investment into early d...
2023-01-10 21:05
3705
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
ROSCREA, Ireland, Jan. 10, 2023 /PRNewswire/ – Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, is pleased to announce opening of the Investigational New Drug ...
2023-01-10 21:00
3365
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer
NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps...
2023-01-10 21:00
3771
CSafe Bolsters Its Digital Ecosystem Launching TracSafe Data Loggers and CSafe Connect Portal
TracSafe fit-for-purpose data loggers link directly to the comprehensive CSafe Connect customer portal creating the next iteration of a progressive customer-focused digital ecosystem MONROE, Ohio, Jan. 10, 2023 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive ...
2023-01-10 20:00
4433
Sarah Otten Joins Medison Pharma as VP, GM Americas Region
Sarah Otten will lead Medison's Americas region covering Canada and Latin
America. Sarah brings vast geographical expansion experience in international
markets.
PETACH TIKVAH, Israel and ZUG, Switzerland, Jan. 9, 2023 /PRNewswire/ --
Medison Pharma
2023-01-10 19:54
2604
Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report
Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions Promising therapeutic developments for HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma and breast cancer on horizon LONDON, Jan. 10, 2023 /PRNewswire/ ...
2023-01-10 16:00
2450
Bangkok Dusit Medical Services extends partnership with CNN to explore global health issues
HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Bangkok Dusit Medical Services Public
Company Limited (BDMS), the largest healthcare network inThailand, reinforces
its long-standing partnership with CNN International Commercial (CNNIC) with
the sponsorship of 'Vital Signs
2023-01-10 11:24
2971
Insilico Medicine Announces Positive Topline Results of the New Zealand Phase I Trial of INS018_055, an AI-Designed Drug for an AI-Discovered Target
NEW YORK and HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Insilico Medicine, a
clinical stage artificial intelligence (AI)-driven drug R&D company, today
announces positive topline results of safety, tolerability, and
pharmacokinetics (PK) from thePhase I clinical trial of INS018_055
2023-01-10 05:00
5930
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
ROCKVILLE, Md. and SUZHOU, China, Jan. 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-01-10 00:00
4258
Luye Pharma's Innovative Anti-Cancer Therapy Lurbinectedin to Benefit "Named Patients" in Hong Kong
HONG KONG, Jan. 9, 2023 /PRNewswire/ -- Luye Pharma Group today announced the launch of the Named Patient Program (NPP) inHong Kong, China, providing eligible local patients immediate access to the innovative anti-cancer therapy Lurbinectedin. Luye Pharma has signed an agreement with Abacus Medic...
2023-01-09 18:57
5128
Parnell Pharmaceuticals Holdings Ltd Announces Extension of Rights Offering
SYDNEY, Jan. 6, 2023 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") today announced the extension of the backstopped rights offering to raise gross proceeds of approximatelyUS$4.0 million (the "Rights Offering"). Under the terms of the Rights Offer...
2023-01-06 15:05
4808
Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
ROCKVILLE, Md. and SUZHOU, China, Jan. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-01-06 12:22
4715
Kira to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that Frederick Beddingfield M.D., Ph.D., Chief Executive Officer, will present a...
2023-01-05 23:30
3377
AMR Action Fund Announces Investment in BioVersys AG
Deal marks Fund's first investment in Europe and advances its mission of enabling the launch of two to four antimicrobials by 2030 BOSTON, Jan. 5, 2023 /PRNewswire/ -- The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing antimicr...
2023-01-05 20:00
8423
Dr. Steve Mark Gan and Gan Advanced Osseointegration Center (GAOC) Group of Companies Honored at the Asia Pacific Enterprise Awards 2022 Regional Edition
SINGAPORE, Jan. 5, 2023 /PRNewswire/ -- Enterprise Asia, the organizer of the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition, is pleased to recognize 25 exemplary business leaders and enterprises acrossAsia which excelled and showcased unparalleled resilience and growth despite the C...
2023-01-05 17:28
3035
Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-01-05 08:00
5048
DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it w...
2023-01-05 08:00
2501
Cognos Therapeutics, Inc. to Become Publicly Listed on Nasdaq via Business Combination with Nocturne Acquisition Corporation
* Cognos Therapeutics is a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and str...
2023-01-05 07:10
5010
Week's Top Stories
Most Reposted
Agoda Establishes Strategic Partnership with Taipei City Government, Promoting International Tourism Development
[Picked up by 310 media titles]
2026-04-16 17:15
Tata Power Collaborates with Databricks to Build Future-Ready Data and AI Platform to Accelerate Energy Transition
[Picked up by 302 media titles]
2026-04-10 11:13
Hai Robotics and Maersk Redefine Fashion Fulfilment with High-Density Robotics at 10-Metre Scale in Singapore
[Picked up by 298 media titles]
2026-04-14 10:00
Blaize and Winmate Announce Strategic Collaboration to Advance Sovereign Edge AI Capabilities for Defense and Critical Infrastructure
[Picked up by 296 media titles]
2026-04-16 18:00
iQIYI to Open Its First Central China Theme Park in Wuhan, Continuing to Bring IP Value Beyond the Screen
[Picked up by 292 media titles]
2026-04-10 11:38
Most Read
NYSE Content Update: Sourcery Founder Molly O'Shea Joins as a Media Partner
2026-04-10 21:14
7956
High Templar Tech Limited Files Its Annual Report on Form 20-F
2026-04-10 18:30
7870